Jawonio is the premier non-profit provider of lifespan services for individuals with developmental disabilities and special needs, dedicating to advancing their independence, well-being, and equality for over 75 years.

High growth multi-therapeutic network of clinical research sites partnering with pharmaceutical, biotechnology, and medical device companies to advance healthcare.

• Strategic business advisor and CFO of rapidly growing genetic services company.

New public company focused on developing products for health and wellness, and specialty beverage markets. • Managed all reporting requirements, and developed business and capital structuring plan. • Successfully brought company public with the merger and management takeover of specialty beverage company.• Negotiated and executed first acquisition deals to become operational.

CLS is the developer of a patented extraction methodology, with vertically integrated operations developing branded consumer products with retail and wholesale divisions.• Negotiated and closed on $25 million acquisition of vertically integrated business, valued at 2X Sales in high growth market where deals averaged 4-5X Sales, or higher.• Worked closely with CEO on transition of public company from R&D phase into an operating business, generating revenue and profit.

In addition to being CFO, David was promoted to the U.S. Senior Executive Management Team, which managed all aspects of the business including strategy, marketing, and operations as a leadership team.

ARRI Rental is a leader in high-end cinematography camera and lighting equipment rental to the feature film, television, advertising, and broadcast events markets. ARRI Rental has multiple locations in the U.S. and Canada. • Successfully led and restructured the Financial, Accounting and IT departments, opened new locations in the U.S. and Canada, and implemented new Performance management program for team.• Co-led North American team of 150 people and managed 12 direct reports.• Led financial statement preparation for the US, and presented to the UK international team, and Board of Directors of parent company in Munich, Germany.

Critical-care immunotherapy company specializing in products used in treatment of sepsis, cardiac surgery, and other life-threatening diseases and illnesses.• Key member of team involved in all aspects of building operations from start-up phase, clinical trials, CE Mark regulatory approval, and the commercialization of proprietary medical device technology platform.• Collaborated with CEO to execute on key strategic objectives to raise capital to fund operations, advance product development, and take company public. • Secured approx. $70 million in equity and debt financings.• Negotiated financing rounds with Venture Capital, institutional, and high net worth investors (Preferred Stock, Common Stock, Convertible Debt).

• Worked on Middle Market corporate finance team on deals ranging from $5M - $300M.• Completed Chase Corporate Finance Analyst Training Program.